Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests

Not Applicable

Not yet recruiting

• Conditions: Multiple Myeloma
• Interventions: Procedure: Bone marow biopsy and aspiration; Diagnostic Test: biochemical and heamatological tests

• Registration Number: NCT05995808
• Lead Sponsor: Sohag University

Brief Summary

Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after non-Hodgkin lymphoma .

There are some serological and clinical criteria that help to detect the stage of MM and predict the patients' prognosis. These criteria include the level of M protein, calcium, haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-08
• Study First Submitted: 2023-08-09
• Study First Submitted QC: 2023-08-09
• Last Update Submitted: 2023-08-09
• Study First Posted: 2023-08-16
• Last Update Posted: 2023-08-16
• Study Start: 2023-09
• Primary Completion: 2024-08
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Patients older than 18 year with newly diagnosed MM.
2. Approval to sign an informed written consent.

Exclusion Criteria

• 1. Patient younger than 18 years. 2.Refusal to sign an informed written consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
diagnostic group	biochemical and heamatological tests	-
diagnostic group	Bone marow biopsy and aspiration	-

Primary Outcome Measures

Name	Time	Method
Cycline D1 expression in bone marrow biopsy of multiple myeloma patient	1 year	Cycline D1 expression in bone marrow biopsy of multiple myeloma patient